Cargando…
Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease
The global pandemic of COVID-19 caused by SARS-CoV-2 continues to spread and poses serious threats to public health and economic stability throughout the world. Thus, to protect the global population, developing safe and effective vaccines is mandatory to control the spread of SARS-CoV-2 pandemic. S...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826065/ https://www.ncbi.nlm.nih.gov/pubmed/33500636 http://dx.doi.org/10.2147/IDR.S288877 |
_version_ | 1783640453317394432 |
---|---|
author | Belete, Tafere Mulaw |
author_facet | Belete, Tafere Mulaw |
author_sort | Belete, Tafere Mulaw |
collection | PubMed |
description | The global pandemic of COVID-19 caused by SARS-CoV-2 continues to spread and poses serious threats to public health and economic stability throughout the world. Thus, to protect the global population, developing safe and effective vaccines is mandatory to control the spread of SARS-CoV-2 pandemic. Since genomic sequences of SARS-CoV-2 and SARS-CoV-1 have similarity and use the same receptor (ACE2), it is important to learn from the development of SARS-CoV-1 vaccines for the development of SARS-CoV-2 vaccines. Normally vaccine development takes 10–15 years but vaccine development against SARS-CoV2 is going on at a very fast pace resulting in almost breakthrough methods of vaccine development by several research institutions. The whole process of vaccine development including clinical trials gets shortened and may be fast tracked to 15–18 months. Global collaborations and increased research efforts among the scientific community have led to more than 214 candidate vaccines globally. The current review highlights the different approaches and technologies used around the world for the design and development of the vaccines and also focuses on the recent status of the SARS-CoV-2 vaccine candidates under development by various institutions to combat the world threat of COVID-19 pandemic. |
format | Online Article Text |
id | pubmed-7826065 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-78260652021-01-25 Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease Belete, Tafere Mulaw Infect Drug Resist Review The global pandemic of COVID-19 caused by SARS-CoV-2 continues to spread and poses serious threats to public health and economic stability throughout the world. Thus, to protect the global population, developing safe and effective vaccines is mandatory to control the spread of SARS-CoV-2 pandemic. Since genomic sequences of SARS-CoV-2 and SARS-CoV-1 have similarity and use the same receptor (ACE2), it is important to learn from the development of SARS-CoV-1 vaccines for the development of SARS-CoV-2 vaccines. Normally vaccine development takes 10–15 years but vaccine development against SARS-CoV2 is going on at a very fast pace resulting in almost breakthrough methods of vaccine development by several research institutions. The whole process of vaccine development including clinical trials gets shortened and may be fast tracked to 15–18 months. Global collaborations and increased research efforts among the scientific community have led to more than 214 candidate vaccines globally. The current review highlights the different approaches and technologies used around the world for the design and development of the vaccines and also focuses on the recent status of the SARS-CoV-2 vaccine candidates under development by various institutions to combat the world threat of COVID-19 pandemic. Dove 2021-01-19 /pmc/articles/PMC7826065/ /pubmed/33500636 http://dx.doi.org/10.2147/IDR.S288877 Text en © 2021 Belete. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Belete, Tafere Mulaw Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease |
title | Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease |
title_full | Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease |
title_fullStr | Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease |
title_full_unstemmed | Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease |
title_short | Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease |
title_sort | review on up-to-date status of candidate vaccines for covid-19 disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826065/ https://www.ncbi.nlm.nih.gov/pubmed/33500636 http://dx.doi.org/10.2147/IDR.S288877 |
work_keys_str_mv | AT beletetaferemulaw reviewonuptodatestatusofcandidatevaccinesforcovid19disease |